Alzheimer Disease
Conditions
Keywords
Alzheimer's Disease, biomarkers, blood
Brief summary
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
Interventions
None listed
Sponsors
Duke University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Alzheimer's Disease Patients: * 50 years and older * AD patient who is seen at the Memory Disorders Clinic * AD diagnosis * Non smoking * No cancer treatment in the last 5 years * Informed consent from the patient or the patient's legally authorized representative (LAR) * Patient and/or LAR able to read and speak English Healthy Control Participants: * 50 years and older * Non smoking * No cancer treatment in the last 5 years * Age matched to AD subject * Able to read and speak English
Exclusion criteria
Alzheimer's Disease Patients: * Known additional neurological disease Healthy Control Participants: * Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biological marker of Alzheimer's disease | Day 1 | Test for blood biological marker of Alzheimer's disease, mtDNA damage |
Countries
United States
Outcome results
None listed